SCHEMBL10241746

SCHEMBL10241746

COc1ccc(-c2csnc2-c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@H](N)CCCCN

nearest known ligand 0.44

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SUV39H2 Q9H5I1 2/20 0.40
ERAP2 Q6P179 5/20 0.38
LNPEP Q9UIQ6 3/20 0.38
ERAP1 Q9NZ08 2/20 0.37
CIT O14578 1/20 0.37
RXFP1 Q9HBX9 1/20 0.35
AAK1 Q2M2I8 3/20 0.35
MEN1 O00255 1/20 0.35
POLB P06746 1/20 0.35
KMT2A Q03164 1/20 0.35
ADORA3 P0DMS8 1/20 0.34
ADORA2B P29275 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10242338 1.00 SUV39H2 (0.40) SUV39H2ERAP2LNPEPERAP1CIT
Hydrochloric Acid SCHEMBL623854 0.99 SUV39H2 (0.39) SUV39H2ERAP2LNPEPERAP1CIT
SCHEMBL10189436 0.95 SUV39H2 (0.38) SUV39H2ERAP2LNPEPERAP1CIT
SCHEMBL10189437 0.95 SUV39H2 (0.38) SUV39H2ERAP2LNPEPERAP1CIT
SCHEMBL10240329 0.89 CIT (0.37) CITRXFP1AAK1MEN1POLB
SCHEMBL10241279 0.89 CIT (0.37) CITRXFP1AAK1MEN1POLB
SCHEMBL10242420 0.89 CIT (0.37) CITRXFP1AAK1MEN1POLB
SCHEMBL10241729 0.89 CIT (0.37) CITRXFP1AAK1MEN1POLB
SCHEMBL10189459 0.89 CIT (0.37) CITRXFP1AAK1MEN1POLB
SCHEMBL3303769 0.88 CIT (0.39) CITRXFP1AAK1MEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130203824-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SUN LIJUN (US) 2013-08-08 US disclosed
US-8399435-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2013-03-19 US disclosed
US-20120040937-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. 2012-02-16 US disclosed
US-8058297-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2011-11-15 US disclosed
US-8058297-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2011-11-15 US disclosed
US-20090270353-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SUN LIJUN 2009-10-29 US disclosed
US-20090270353-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SUN LIJUN 2009-10-29 US disclosed
US-7572821-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2009-08-11 US disclosed
US-7572821-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2009-08-11 US disclosed
US-20070179159-A1 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. 2007-08-02 US disclosed
US-20070179159-A1 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. 2007-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179159-A1 Compounds for the treatment of proliferative disorders RB1, MKI67, MAPRE1 SUV39H2 2439/4885ERAP2 4040/4885LNPEP 3723/4885
US-20120040937-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 SUV39H2 2439/4885ERAP2 4040/4885LNPEP 3723/4885
US-20090270353-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 SUV39H2 2439/4885ERAP2 4040/4885LNPEP 3723/4885
US-20130203824-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 SUV39H2 2439/4885ERAP2 4040/4885LNPEP 3723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.